The purse strings remain loose for Boston, USA-based Alexion Pharmaceuticals (Nasdaq: ALXN), with the announcement of two new pipeline-boosting collaborations in Europe.
In Sweden, the firm has agreed a deal with Affibody to develop ABY-039 for certain rare autoimmune diseases.
Currently in Phase I development, ABY-039 is a bivalent antibody-mimetic specially designed to have a long half-life, which enables less frequent injections, and a patient-friendly at-home form of administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze